Soleno Therapeutics (SLNO) · page 17 of 415
The slide highlights a discrepancy between the FDA label's explicit warnings about DKA and the company's omission of this risk in their phase 3 and open-label manuscripts.
Activist deck · expose_contradiction · expose_contradiction · overcrowded density
Slide locked Sign in to view
Slide schematic 0/6
∅
No component coordinates
This slide has extracted components, but no normalized bbox values yet.
image 0/1 list 0/1 paragraph 0/3 source-note 0/1
6 without position image 1 · list 1 · paragraph 3 · source-note 1
image · screenshotlist · bulletparagraph · paragraphparagraph · paragraphparagraph · paragraphsource-note
Components 7
screenshot bullet paragraph paragraph paragraph source-note headline
Tools 0
∅
No tools
No canon tool match is anchored to this slide.
Metrics 0
∅
No metrics
No metric insight is anchored to this slide.
Frameworks 1